Ian Chau
#137,065
Most Influential Person Now
Researcher
Ian Chau's AcademicInfluence.com Rankings
Ian Chaucomputer-science Degrees
Computer Science
#6338
World Rank
#6685
Historical Rank
Computational Linguistics
#1068
World Rank
#1082
Historical Rank
Machine Learning
#2023
World Rank
#2049
Historical Rank
Artificial Intelligence
#2275
World Rank
#2314
Historical Rank
Download Badge
Computer Science
Ian Chau's Degrees
- Masters Artificial Intelligence Stanford University
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Ian Chau Influential?
(Suggest an Edit or Addition)Ian Chau's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. (2004) (3841)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. (2018) (2082)
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial (2014) (1725)
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. (2015) (1386)
- Patient-derived organoids model treatment response of metastatic gastrointestinal cancers (2018) (981)
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. (2016) (975)
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial (2018) (791)
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial (2013) (651)
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. (2015) (639)
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. (2016) (616)
- Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. (2009) (600)
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. (2014) (487)
- Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. (2004) (486)
- Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. (2006) (426)
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer (2018) (381)
- Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). (2012) (356)
- Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial (2013) (349)
- Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. (2010) (300)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021) (280)
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (263)
- Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. (2015) (247)
- First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials (2017) (240)
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study (2017) (230)
- Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 (2018) (220)
- A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. (2011) (207)
- High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. (2016) (205)
- BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study (2018) (188)
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (185)
- Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. (2018) (181)
- A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. (2005) (179)
- PHASE III RANDOMISED COMPARISON OF GEMCITABINE (GEM) WITH GEMCITABINE PLUS CAPECITABINE (GEM-CAP) IN PATIENTS WITH ADVANCED PANCREATIC CANCER (2005) (168)
- Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. (2022) (166)
- Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial (2009) (165)
- Adjuvant therapy in colon cancer--what, when and how? (2006) (164)
- Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. (2018) (159)
- The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. (2004) (154)
- Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. (2019) (153)
- Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination (2008) (151)
- Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. (2019) (148)
- Guidance on the management of diarrhoea during cancer chemotherapy. (2014) (148)
- Patients’ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey (2016) (143)
- Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. (2009) (142)
- Targeting the human EGFR family in esophagogastric cancer (2011) (139)
- Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer (2018) (139)
- Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer (2013) (131)
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. (2010) (128)
- Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging. (2008) (127)
- Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. (2002) (126)
- Rapid access multidisciplinary lymph node diagnostic clinic: analysis of 550 patients (2003) (117)
- Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF) (2018) (116)
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. (2021) (111)
- Treatment in advanced colorectal cancer: what, when and how? (2009) (111)
- Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer (2017) (106)
- Does surgery have a role in managing incurable gastric cancer? (2015) (102)
- Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases. (2012) (100)
- Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. (2007) (99)
- Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study (2021) (97)
- CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). (2016) (88)
- Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (87)
- Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. (2015) (86)
- Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment (2019) (83)
- Adjuvant therapy in colon cancer: current status and future directions. (2002) (82)
- Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. (2017) (82)
- Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab (2017) (81)
- Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer (2003) (80)
- Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score (2017) (78)
- Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: A pooled analysis of four randomised trials. (2018) (78)
- Correction to: "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". (2019) (75)
- Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer (2003) (75)
- Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. (2017) (71)
- Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. (2016) (70)
- Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? (2003) (70)
- MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy--implications for induction chemotherapy? (2013) (70)
- Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer (2014) (69)
- Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials (2006) (68)
- Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy (2004) (67)
- FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. (2014) (65)
- PD-1 and PD-L1 blockade in gastrointestinal malignancies. (2015) (64)
- Timing of Surgery Following Preoperative Therapy in Rectal Cancer: The Need for a Prospective Randomized Trial? (2011) (64)
- Longitudinal Assessment of Quality of Life in Rectal Cancer Patients With or Without Stomas Following Primary Resection (2009) (63)
- PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. (2016) (62)
- Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM‐P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non‐Hodgkin's lymphoma (2003) (61)
- An oxaliplatin‐based chemotherapy in patients with relapsed or refractory intermediate and high‐grade non‐Hodgkin's lymphoma (2001) (60)
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. (2017) (60)
- Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. (2020) (60)
- A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). (2012) (58)
- Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study (2017) (57)
- Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. (2009) (56)
- EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. (2014) (56)
- MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer (2019) (55)
- Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study. (2021) (54)
- The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. (2009) (54)
- The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. (2010) (53)
- CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids (2019) (53)
- Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab (2016) (52)
- Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2 (2021) (52)
- TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. (2014) (52)
- Optimal Management of Gastric Cancer: Results From an International RAND/UCLA Expert Panel (2014) (52)
- Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2 (2021) (52)
- Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data (2017) (51)
- Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone? (2014) (50)
- Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma (2005) (50)
- The vital role of education and information in patients receiving capecitabine (Xeloda). (2004) (49)
- The genomic landscape of oesophagogastric junctional adenocarcinoma (2013) (49)
- KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer (2018) (49)
- A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. (2004) (49)
- Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. (2018) (48)
- Novel STAT 3 inhibitors for treating gastric cancer (2016) (47)
- Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. (2015) (47)
- Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies (2016) (45)
- CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial (2018) (45)
- Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. (2013) (45)
- Folate Metabolism Polymorphisms Influence Risk of Colorectal Adenoma Recurrence (2006) (44)
- Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline (2021) (44)
- Ultra-sensitive mutation detection and genome-wide DNA copy number reconstruction by error corrected circulating tumour DNA sequencing (2017) (43)
- Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. (2013) (42)
- Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives. (2003) (42)
- Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. (2019) (41)
- Chemotherapy in colorectal cancer: new options and new challenges. (2002) (41)
- Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. (2015) (40)
- Treatment and Survival Outcome of BRAF‐Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case‐Control Study (2017) (40)
- Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience (2015) (40)
- The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis. (2013) (40)
- A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI (2014) (39)
- miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial (2016) (39)
- Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens (2019) (39)
- Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial (2021) (38)
- Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. (2006) (38)
- Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. (2014) (38)
- EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. (2014) (37)
- Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality? (2002) (37)
- Efficacy of Vemurafenib in Patients With Non–Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study (2019) (36)
- Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. (2019) (35)
- VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). (2014) (34)
- Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection (2012) (33)
- Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer (2021) (33)
- Deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (Watch and Wait) study: A phase II multicenter study in the United Kingdom. (2011) (33)
- RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. (2018) (33)
- Patupilone in cancer treatment (2011) (32)
- Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. (2011) (32)
- Pancreatic neuroendocrine tumors: a review. (2015) (32)
- Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. (2021) (32)
- Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions. (2016) (31)
- A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers. (2014) (31)
- Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study (2020) (31)
- COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. (2013) (31)
- Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. (2019) (31)
- Management of resectable colorectal lung metastases (2016) (30)
- MRI-Diagnosed Tumor Deposits and EMVI Status Have Superior Prognostic Accuracy to Current Clinical TNM Staging in Rectal Cancer (2020) (30)
- HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. (2013) (30)
- Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. (2017) (30)
- Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated {alpha}-fetoprotein (AFP) from the randomized phase III REACH study. (2015) (30)
- RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. (2014) (30)
- Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). (2011) (29)
- Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin‐based Chemotherapy in Colorectal Cancer (2018) (29)
- Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum (2015) (28)
- Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients (2018) (28)
- A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. (2019) (27)
- Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. (2005) (27)
- Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified? (2016) (27)
- Matrix metalloproteinase inhibitors--an emphasis on gastrointestinal malignancies. (2003) (27)
- Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients (2019) (27)
- Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial. (2020) (27)
- Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF). (2018) (26)
- Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. (2021) (26)
- LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen (2021) (26)
- A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. (2016) (26)
- Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial (2015) (26)
- Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study (2018) (25)
- The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. (2014) (25)
- A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). (2013) (25)
- miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial (2019) (25)
- Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer. (2017) (25)
- Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases (2012) (25)
- Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. (2009) (25)
- Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P). (2017) (25)
- Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors. (2014) (24)
- Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer (2001) (24)
- Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study. (2018) (24)
- A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. (2012) (24)
- CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer. (2017) (24)
- Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. (2013) (23)
- Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA. (2013) (23)
- LBA16RAMUCIRUMAB (RAM) AS SECOND-LINE TREATMENT IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING FIRST-LINE THERAPY WITH SORAFENIB: RESULTS FROM THE RANDOMIZED PHASE III REACH STUDY (2014) (23)
- Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. (2018) (23)
- A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma (2009) (22)
- Preoperative and postoperative chemotherapy for gastric cancer. (2012) (22)
- Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes (2017) (22)
- Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours (2020) (21)
- Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer (2020) (21)
- Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer. (2014) (21)
- Gastric Cancer - From Aetiology to Management: Differences Between the East and the West. (2019) (21)
- 6076 BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection (2009) (21)
- Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03). (2020) (21)
- Molecular target: pan-AKT in gastric cancer (2020) (20)
- BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC) (2018) (20)
- Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. (2015) (20)
- Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy. (2020) (20)
- Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW (2018) (19)
- Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center (2019) (19)
- Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study (2021) (19)
- Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013 (2017) (19)
- A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. (2014) (19)
- Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice (2018) (19)
- VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). (2014) (19)
- Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. (2020) (19)
- EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers (2020) (19)
- Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer (2017) (19)
- Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study. (2017) (19)
- CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma. (2018) (18)
- CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer. (2017) (18)
- EXPERT-C: A randomized phase II European multicenter trial of neoadjuvant chemotherapy (capecitabine/oxaliplatin) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk rectal cancer. (2011) (18)
- Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma (2015) (18)
- Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies. (2013) (18)
- The Role of Routine Clinical Pretreatment 18F-FDG PET/CT in Predicting Outcome of Colorectal Liver Metastasis (2015) (18)
- The effect of a primary tumour resection on the progression of synchronous colorectal liver metastases: an exploratory study. (2015) (18)
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH). (2018) (18)
- Gemcitabine and its combinations in the treatment of malignant lymphoma. (2002) (17)
- Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results. (2016) (17)
- Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil (2003) (16)
- EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer. (2011) (16)
- Rechallenge with Platinum plus Fluoropyrimidine +/– Epirubicin in Patients with Oesophagogastric Cancer (2010) (16)
- Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. (2019) (16)
- Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer. (2020) (16)
- Oxaliplatin for colorectal cancer in the United States: better late than never. (2003) (16)
- Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging. (2016) (16)
- Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase Ill trial of gefitinib versus placebo (TRANS-COG). (2014) (16)
- Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). (2019) (15)
- Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study (2016) (15)
- Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC). (2021) (15)
- Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. (2021) (15)
- Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial (2020) (15)
- Mucosa associated lymphoid tissue lymphoma of the lung: The Royal Marsden Hospital experience (2007) (15)
- Cougar-02 : a randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma (2013) (15)
- Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer (2019) (14)
- Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction (2010) (14)
- A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. (2012) (14)
- Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients (2016) (14)
- Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt? (2019) (13)
- ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. (2019) (13)
- A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117). (2015) (13)
- Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials (2020) (13)
- 305 Twelve weeks of neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation (CRT) and total mesorectal excision (TME) in MRI defined poor risk locally advanced rectal cancer resulted in promising tumour regression and rapid symptomatic relief (2003) (13)
- What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel. (2013) (12)
- Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC) (2019) (12)
- Checkpoint inhibition: an ATTRACTION in advanced gastric cancer? (2017) (12)
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH). (2018) (12)
- Gemcitabine Plus Capecitabine in Unselected Patients With Advanced Pancreatic Cancer (2013) (12)
- Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study (2015) (12)
- REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II. (2011) (12)
- Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma (2019) (12)
- Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status (2010) (12)
- Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study (2020) (12)
- Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL) (2007) (12)
- Neoadjuvant rectal score: run with the hare and hunt with the hounds. (2018) (11)
- Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐GEM‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma (2015) (11)
- NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroend (2020) (11)
- POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study. (2019) (11)
- Genomic loss of heterozygosity and survival in the REAL3 trial (2018) (11)
- Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. (2003) (11)
- Neoadjuvant chemotherapy alone for early-stage rectal cancer: an evolving paradigm? (2011) (11)
- The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy (2020) (11)
- Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer (2021) (11)
- TP53 status may predict benefit from cetuximab in high-risk, locally advanced rectal cancer: Results of the EXPERT-C trial (2013) (11)
- Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. (2020) (11)
- The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma: The TARGET study. (2010) (11)
- Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines‐Pretreated or High‐Risk Cardiac Patients With GI Malignancies: Large Single‐Center Experience (2019) (10)
- GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma (2014) (10)
- A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR). (2012) (10)
- Phase I study to evaluate the safety and efficacy of sunitinib in combination with FOLFIRI in treatment-naive metastatic colorectal cancer (mCRC) (2008) (10)
- Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. (2017) (10)
- MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types. (2018) (10)
- Neoadjuvant therapy before surgical treatment (2013) (10)
- Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma (2020) (10)
- Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation. (2017) (10)
- HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer (2018) (9)
- Variations in outcome for advanced gastric cancer between Japanese and Western patients: a subgroup analysis of the RAINBOW trial. (2016) (9)
- Molecular subtype assay to reveal anti-EGFR response sub-clones in colorectal cancer (CRC). (2018) (9)
- Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital (2018) (9)
- Phase I study of gefitinib in combination with irinotecan in patients with fluoropyrimidine refractory advanced colorectal cancer (CRC) (2004) (9)
- Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001–2010 (2016) (9)
- 1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen (2022) (8)
- Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. (2017) (8)
- SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy. (2022) (8)
- Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02). (2021) (8)
- Immunotherapy for oesophagogastric cancer (2016) (8)
- Targeting the Stroma in the Management of Pancreatic Cancer (2021) (8)
- Claudin 18.2 - a FAST-moving target in gastric cancer? (2021) (8)
- Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment (2017) (8)
- O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma (2020) (7)
- Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions (2015) (7)
- Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk (2020) (7)
- 674PNivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032 (2017) (7)
- Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. (2019) (7)
- Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032 (2018) (7)
- Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies (2019) (7)
- A dose-escalation study of gemcitabine (Gem) plus oxaliplatin (Ox) in combination with imatinib in patients (pts) with gemcitabine-refractory advanced pancreatic adenocarcinoma (PC). (2010) (7)
- Ramucirumab: targeting angiogenesis in the treatment of gastric cancer. (2014) (7)
- 386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC) (2021) (7)
- Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial (2013) (7)
- MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer. (2018) (7)
- A randomised comparison between six months of bolus fluorouracil (5-FU)/leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5-FU as adjuvant treatment in colorectal cancer: An update with 5 years' follow-up. (2004) (7)
- Bevacizumab-associated gastrointestinal perforation. (2009) (7)
- A multicenter phase II clinical study evaluating the deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (CRT). (2010) (7)
- Timing of Therapies in the Multidisciplinary Treatment of Locally Advanced Rectal Cancer: Available Evidence and Implications for Routine Practice. (2016) (7)
- O-0025RANDOMISED, PHASE 2 STUDY (OLIVIA) OF BEVACIZUMAB PLUS MFOLFOX6 OR FOLFOXIRI IN PATIENTS WITH INITIALLY UNRESECTABLE COLORECTAL CANCER LIVER METASTASES (2013) (7)
- Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC). (2014) (6)
- 145OValidated nCounter platform to stratify colorectal cancer (CRC) into Consensus Molecular Subtypes (CMS) and CRCassigner subtypes in Asian population (2017) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Clinical Performance of Abbreviated Liver MRI for the Follow-Up of Patients With Colorectal Liver Metastases. (2021) (6)
- JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma. (2014) (6)
- FcγRIIa and FcγRIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease (2014) (6)
- Corrigendum to "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]. (2022) (6)
- 6097 POSTER Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer – Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification (2011) (6)
- HER2 targeted therapy in colorectal cancer: New horizons. (2022) (6)
- Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study (2020) (6)
- A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer. (2016) (6)
- Evaluation of the role of MRI in staging rectal cancer within the multidisciplinary team setting (2004) (6)
- Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC (2021) (6)
- Ramucirumab and its use in the treatment of hepatocellular carcinoma. (2019) (6)
- Primary follicular lymphoma of the GI tract: an increasingly recognized entity. (2012) (6)
- Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL). (2015) (6)
- A phase I study of pazopanib in combination with FOLFOX 6 or capeOx in subjects with colorectal cancer. (2009) (6)
- Trastuzumab for gastric cancer treatment (2010) (5)
- Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25]. (2018) (5)
- Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma. (2017) (5)
- Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy. (2018) (5)
- The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology. (2015) (5)
- Perioperative FLOT plus anti-PD-L1 avelumab (FLOT-A) in resectable oesophagogastric adenocarcinoma (OGA): Interim safety analysis results from the ICONIC trial. (2021) (5)
- Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma. (2017) (5)
- An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer (2013) (5)
- Investigational therapies targeting the ErbB family in oesophagogastric cancer (2014) (5)
- Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer. (2018) (5)
- Attitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies (2017) (5)
- Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patients (2018) (5)
- Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer (2020) (5)
- MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF) (2019) (5)
- PLATFORM: Planning treatment of oesophago-gastric (OG) cancer—A randomised maintenance therapy trial. (2016) (5)
- CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer. (2017) (5)
- Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma (2016) (5)
- Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage (2021) (5)
- Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab (2017) (5)
- Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma? (2018) (5)
- 2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment (2015) (4)
- Capecitabine in gastric cancer. (2008) (4)
- Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer. (2018) (4)
- Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP) (2016) (4)
- A RAND/UCLA Appropriateness Study of the Management of Familial Gastric Cancer (2013) (4)
- Histologically Proven Myocardial Carcinoid Metastases: The Value of Multimodality Imaging. (2017) (4)
- Genomic loss of heterozygosity (LOH) and survival in patients (pts) treated with epirubicin, oxaliplatin, capecitabine (EOC) ± panitumumab (P) in the REAL3 trial (2016) (4)
- A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial (2021) (4)
- Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma (2021) (4)
- Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials. (2017) (4)
- Capecitabine in advanced gastric cancer (2007) (4)
- A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study. (2017) (4)
- Phase I study of gefitinib in combination with irinotecan in patients with fluoropyrimidine refractory advanced colorectal cancer (CRC). (2004) (4)
- 642PSurvival in advanced oesophagogastric adenocarcinoma (OGA) improves with the use of multiple lines of therapy: Results from an analysis of over 500 patients (pts) (2017) (4)
- The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing (2021) (4)
- Abstract LB-67: REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line p (2013) (4)
- Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer (2017) (4)
- TAK‐659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT‐3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE‐ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY (2017) (4)
- 3065 POSTER Safety and efficacy of sunitinib and FOLFIRI in combination in treatment-naive metastatic colorectal cancer (mCRC): a phase I study (2007) (4)
- Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma (2018) (4)
- R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial (2019) (4)
- Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials (2018) (4)
- A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. (2012) (4)
- 443P EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers – phase IIA dose finding (2021) (4)
- Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches (2018) (4)
- HER 2 in high-risk rectal cancer patients treated in EXPERT-C , a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin ( CAPOX ) and chemoradiotherapy ( CRT ) with or without cetuximab (4)
- Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study (2016) (4)
- Percutaneous radiofrequency versus microwave ablation for the treatment of colorectal liver metastases. (2018) (3)
- Rare case of cerebral MALToma presenting with stroke-like symptoms and seizures (2013) (3)
- A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas (2020) (3)
- 18F‐choline radiotracer positron emission tomography as a new means to monitor central nervous system lymphoma (2021) (3)
- Systemic chemotherapy (CT) as salvage treatment for locally advanced rectal cancer (LARC) patients (pts) who fail to respond to neoadjuvant chemoradiotherapy (CRT). (2017) (3)
- Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer. (2019) (3)
- RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC). (2014) (3)
- CHOP VERSUS GEM‐P IN THE FIRST‐LINE TREATMENT OF T‐CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NRCI PHASE II RANDOMISED CHEMO‐T TRIAL (2017) (3)
- Maximal response to infusional chemotherapy prior to autotransplantation influences outcome of patients with newly-diagnosed multiple myeloma (2000) (3)
- Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study. (2017) (3)
- LyRIC indeterminate response and Immune‐mediated pseudoprogression of diffuse large B‐cell lymphoma following polatuzumab‐based salvage therapy (2020) (3)
- DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases (2021) (3)
- Abstract 258: MicroRNAs as biomarkers of resistance to HER2 inhibition in combination with chemotherapy in gastro-esophageal cancer (2020) (3)
- 222 Gastrazole, a novel CCKB/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials (2003) (3)
- Updated survival analysis of EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab in MRI-defined high risk rectal cancer patients (2013) (3)
- Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade (2016) (3)
- Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC). (2020) (3)
- Elderly patients with fluoropyrimidine-resistant advanced colorectal cancer (CRC) derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. (2004) (3)
- Antibodies against endogenous retroviruses promote lung cancer immunotherapy (2023) (3)
- O-0008REGARD PHASE 3, RANDOMIZED TRIAL OF RAMUCIRUMAB IN PATIENTS WITH METASTATIC GASTRIC OR GEJ ADENOCARCINOMA FOLLOWING PROGRESSION ON FIRST-LINE CHEMOTHERAPY (2013) (3)
- Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty (2017) (3)
- Are treatment response assessment maps (TRAMs) and 18F‐choline positron emission tomography the future of central nervous system lymphoma imaging? (2021) (3)
- Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019 (2020) (3)
- Is front-line checkpoint blockade ATTRACTIVE in advanced gastric cancer? (2019) (3)
- Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF). (2019) (2)
- Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. (2021) (2)
- Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials. (2018) (2)
- Nonsurgical management of esophageal adenocarcinoma. (2011) (2)
- Focal splenic lesions in indolent B‐NHL: association with high grade transformation and safe percutaneous biopsy (2020) (2)
- 145OPhase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort clinical and translational results (2015) (2)
- 1416P Genomic landscape of late-stage gastric cancer (2021) (2)
- Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study. (2017) (2)
- Elderly patients with fluoropyrimidine-resistant advanced colorectal cancer (CRC) derive similar benefit without excessive toxicity when treated with irinotecan monotherapy (2004) (2)
- Extramural venous invasion (EMVI) is a potential imaging predictive biomarker in rectal cancer (2013) (2)
- Comparison between magnetic resonance imaging (MRI) and pathology in the assessment of tumour regression grade (TRG) in rectal cancer (RC) (2017) (2)
- O-005Ramucirumab (RAM) as second-Line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: comprehensive results from the randomized phase III REACH study (2015) (2)
- Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas (2016) (2)
- Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts (2017) (2)
- Neoadjuvant chemotherapy for gastric cancer (2012) (2)
- Whole-body diffusion-weighted MRI in lymphoma-comparison of global apparent diffusion coefficient histogram parameters for differentiation of diseased nodes of lymphoma patients from normal lymph nodes of healthy individuals. (2021) (2)
- Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study. (2015) (2)
- Assessment of combination treatment with gemcitabine, cisplatin, and methylprednisolone (Gem-P) in the management of non-Hodgkin T-cell lymphoma. (2010) (2)
- Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF. (2020) (2)
- Digital histological markers based on routine H&E slides to predict benefit from maintenance immunotherapy in esophagogastric adenocarcinoma. (2021) (2)
- Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials (2022) (2)
- Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology (2016) (2)
- Session 3: Beyond TME and radiotherapy MRI evaluation of rectal cancer treatment response (2018) (2)
- Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme. (2019) (2)
- P-0196A VELOUR POST HOC SUBSET ANALYSIS: PROGNOSTIC GROUPS AND TREATMENT OUTCOMES IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) TREATED WITH AFLIBERCEPT AND FOLFIRI (2013) (2)
- Colon and rectum (2017) (2)
- Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648. (2022) (2)
- Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03). (2019) (2)
- EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers (2019) (2)
- Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma (2021) (2)
- Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202). (2017) (2)
- Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma (2021) (2)
- Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma. (2014) (2)
- Complications and seeding risk after percutaneous liver biopsy in an oncological setting. (2018) (2)
- Association of high-throughput RNAi and drug screening with candidate novel therapeutic targets in esophageal carcinoma. (2013) (2)
- IS6–4ANTI-CD30 ANTIBODY DRUG CONJUGATE THERAPY IN HODGKIN LYMPHOMA AND CD30+ LYMPHOMA (2013) (2)
- Survival in advanced oesophagogastric adenocarcinoma improves with the use of multiple lines of therapy: results from an analysis of over 500 patients (2018) (2)
- Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial. (2021) (2)
- Circulating tumour DNA (ctDNA) as a tool to assess response and guide therapy adaptation in rectal cancer. (2018) (2)
- Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma. (2017) (2)
- Chronic lymphocytic leukaemia and Richter's transformation: multimodal review and new imaging paradigms. (2021) (2)
- Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): Results from the FOXFIRE prospective randomized studies (2017) (2)
- EGFR amplification (amp) and survival in the REAL-3 trial. (2018) (2)
- iMYC: Proof-of-concept study of ibrutinib in c-MYC and HER2 amplified oesophagogastric carcinoma. (2017) (1)
- Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre (2018) (1)
- Abstract 3589: Validation of the role of circulating tumor DNA (ctDNA) in tracking mechanisms of resistance to anti-EGFR monoclonal antibodies (AE-mABs): preliminary results of the PROSPECT-C prospective trial (2015) (1)
- Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis. (2018) (1)
- Abstract 4339: Molecular subtypes and novel genetic mechanisms of primary and acquired anti-EGFR resistance in colorectal cancer in the Prospect C biomarker trial (2018) (1)
- 51 The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer: analysis from a prospective randomised controlled trial (2003) (1)
- Meaningful changes in quality of life (QoL) in patients with gastric cancer: Exploratory analyses from RAINBOW and REGARD. (2017) (1)
- Do investigational MET inhibitors have potential for the treatment of gastric cancer? (2019) (1)
- 571PMultiplatform assay to classify formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) samples into molecular subtypes with mutational profiles (2017) (1)
- THE ROLE OF 18F FDG‐PET/CT IN PERIPHERAL T‐CELL LYMPHOMA (PTCL): INITIAL RESULTS OF THE UK NCRI MULTICENTRE PHASE II RANDOMISED CHEMO‐T TRIAL PET/CT SUBSTUDY (2017) (1)
- EXCELLENT OUTCOMES USING RITUXIMAB, GEMCITABINE, CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISOLONE (R‐GCVP) IN PATIENTS WITH DLBCL AND CARDIAC COMORBIDITIES (2019) (1)
- Cytokine release syndrome in a patient with colorectal cancer following vaccination with BNT162b2 (tozinameran) (2021) (1)
- Emerging precision therapies for gastric cancer (2020) (1)
- A Randomised Multicentre Trial of Epirubicin, Oxaliplatin and Capecitabine (EOC) + Panitumumab in advanced Oesophago-Gastric Cancer (REAL3): Updated Results (2012) (1)
- Gemcitabine (GEM), cisplatin (P) and methylprednisolone: A salvage regimen in relapsed Hodgkin's disease and non-Hodgkin's lymphoma. (2004) (1)
- Outcomes of patients (pts) with BRAF mutated (BRAF MT) Colorectal Cancer (CRC): The Royal Marsden Experience. (2016) (1)
- Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials (2021) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Prospective study of genetic mutations in matched tumor and plasma specimens in colorectal cancer patients. (2011) (1)
- Associations of quality of life (QoL) with adverse events and tumor response in patients with advanced gastric cancer: Exploratory analyses from RAINBOW and REGARD. (2017) (1)
- Investigating the feasibility of precision medicine in gastrointestinal cancers (2016) (1)
- Upper gastrointestinal malignancies: a new era in clinical colorectal cancer. (2009) (1)
- Rash, neutrophil-lymphocyte ratio (NLR) and survival in the REAL3 trial (2017) (1)
- Prospective analysis of microRNA 31-3p (miR31-3p) as a predictive biomarker of response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mABs) in patients with metastatic colorectal cancer (mCRC). (2019) (1)
- Initial safety run-in findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer. (2020) (1)
- A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial (2019) (1)
- HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target (2022) (1)
- Does histology influence outcome in advanced oesophagogastric (OG) cancer? Individual patient data from 1,680 patients on three randomised controlled trials (RCT) (2007) (1)
- Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in a predominanty gastrointestinal oncology patient population, treated at the Royal Marsden (RM) Hospital. (2017) (1)
- Survival of chemotherapy (chemo) refractory gastric or gastroesophageal junction cancer (GC/GEJC) patients from Flatiron Health (FH): Matched clinical characteristics to ATTRACTION-2 and CHECKMATE-032. (2018) (1)
- KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial (2016) (1)
- The EASI-SWITCH trial: Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis. (2016) (1)
- NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC). (2022) (1)
- 439P Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC) (2020) (1)
- BACCHUS: A randomised study of neoadjuvant chemotherapy alone in patients with high-risk locally advanced rectal cancer. (2017) (1)
- Abstract 4977: MIR1307 mediates pancreatic cancer resistance to FOLFIRINOX chemotherapy by affecting response to DNA damage (2018) (1)
- Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013 (2014) (1)
- A very rare complication of subdural haematoma: fibrin‐associated diffuse large B‐cell lymphoma (2020) (1)
- Gemcitabine, cisplatin and methylprednisolone (GEM-P) in patients with T-cell lymphoma: Results from The Royal Marsden Hospital. (2006) (1)
- Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial. (2014) (1)
- Clinical trial end points relevant to patients and society for rare cancers (2015) (1)
- Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score. (2015) (1)
- Correction to: Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer (2019) (1)
- Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study. (2017) (1)
- 1386P Phase II study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (pembro) in advanced gastric or gastroesophageal junction (GEJ) cancer (2021) (1)
- Evaluating maintenance therapies in advanced oesophago-gastric adenocarcinoma (OGA): Interim analysis and biomarker results from the PLATFORM study. (2020) (1)
- Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer (2022) (1)
- Prognostic factor analysis of overall survival (OS) in gastric cancer from two phase III studies of second-line ramucirumab (RAM) (REGARD and RAINBOW) using pooled individual patient (pt) data. (2015) (1)
- Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial. (2015) (1)
- 1226P Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay (2022) (1)
- Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data (2020) (1)
- Bevacizumab and combination chemotherapy in rectal cancer until surgery (BACCHUS): A phase II, multicenter, open-label, randomized study of neoadjuvant chemotherapy alone without radiation in patients with MRI-defined high-risk cancer of the rectum not threatening the circumferential margin. (2014) (1)
- Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer. (2021) (1)
- Optimising longitudinal plasma-only circulating tumour DNA (ctDNA) for minimal residual disease (MRD) detection with combined genomic/methylation signals to predict recurrence in patients (pts) with resected stage I-III colorectal cancer (CRC) in the UK multicentre prospective study TRACC. (2023) (0)
- Management of resectable colorectal lung metastases (2015) (0)
- Platinum-fluoropyrimidine (PF) and paclitaxel (PTX)-based chemotherapy (CT) in advanced anal cancer (AC) (2016) (0)
- Treatment of relapsed oesophagogastric adenocarcinoma after perioperative chemotherapy and surgery. (2019) (0)
- Health-related quality of life (HRQoL) in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC) treated with nivolumab (N) plus chemotherapy (CT) or nivo plus ipilimumab (I) versus chemo: Results from CheckMate 648. (2022) (0)
- Outcomes of Peripheral T-cell Lymphoma in the Current Era: 10 Year Experience at The Royal Marsden and Christie Hospitals. (2015) (0)
- Efficacy, safety, and cancer-related symptoms in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400 ng/ml: A pooled analysis from REACH and REACH-2 studies (2019) (0)
- 1446P Initial safety and efficacy findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer (2020) (0)
- Old and New Therapies for GEP NETs (2014) (0)
- Does R-IPI Remain Predictive of Relapse Risk for Patients with DLBCL Achieving a Complete Remission with Frontline Therapy: Landmark Analysis of Two Large Prospective Clinical Trials (2022) (0)
- What is the outcome of receiving subsequent therapy among patients (pts) with advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC)? Experience from electronic health records (EHR). (2018) (0)
- Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA). (2023) (0)
- Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012 (2015) (0)
- Optimising management of poor risk localised colorectal cancer and fluorouracil pre-treated advance colorectal cancer. (2006) (0)
- Impact of infiltrating T cell subtypes on survival and response to FLOT chemotherapy in resectable oesophagogastric adenocarcinoma (OGA). (2023) (0)
- Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study (2022) (0)
- Gefitinib and irinotecan in patients with fluoropyrimidine-refractory irinotecan-naïve advanced colorectal cancer (CRC): dose-finding, pharmacokinetics, safety and efficacy. (2016) (0)
- Cetuximab in colon cancer - Reply (2004) (0)
- Longitudinal quality of life (QoL) and quality adjusted survival (QAS) in a randomised controlled trial (RCT) comparing bolus (24 weeks) vs. protracted venous infusion (PVI 12 weeks) 5-FU as adjuvant chemotherapy for colorectal cancer (CRC). (2004) (0)
- CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids. (2019) (0)
- NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC). (2023) (0)
- Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials. (2023) (0)
- Two large, global phase 3 trials have confirmed the efficacy of the vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab in the second-line treatment of advanced gastric cancer (GC) and gastro- (2016) (0)
- Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC). (2019) (0)
- Epidemiology Projection Trends for Metastatic Colorectal Cancer (MCRC) Patients Receiving Second Line (2L) Therapy in EU and US (2012) (0)
- P-0172 Distribution of Kras Status Across Treatment Patterns In 1st and 2nd Line Metastatic Colorectal Cancer (MCRC) Patients in Western Europe (2012) (0)
- Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre (2023) (0)
- Advances in Molecular Subclassification of Colorectal Cancer (2018) (0)
- 162PReal world use of palliative systemic therapy (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) within a UK specialist cancer centre (2017) (0)
- 199PCisplatin substitution with carboplatin during radical chemoradiation (CRT) for localised gastroesophageal carcinoma (GEC): Outcomes from a tertiary referral centre (2017) (0)
- Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648. (2023) (0)
- IS1-4DESIGNING THERAPEUTIC TRIAL IN METASTATIC GASTRIC CANCER IN 2014 (2014) (0)
- Focal Splenic Lesions May Identify Patients Who Benefit from Anthracycline Based Therapy and Are Significantly Associated with High Grade Transformation in Follicular Lymphoma (2017) (0)
- The Arroven Study (Ma25101): Post-Authorisation Observational Safety Study of Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma (2015) (0)
- 1253P Safety and efficacy of Wnt inhibition with a DKK1 inhibitor, DKN-01, in combination with atezolizumab in patients with advanced oesophagogastric adenocarcinoma: Phase IIa results of the WAKING trial (2022) (0)
- POST-AUTHORISATION OBSERVATIONAL SAFETY STUDY OF BRENTUXIMAB VEDOTIN IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA AND SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA: ARROVEN STUDY (2015) (0)
- 195PCarboplatin for operable oesophageal and gastric adenocarcinoma (OGA): Royal Marsden (RMH) experience 2001-2010 (2015) (0)
- Safety and effectiveness of aflibercept + FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): OZONE secondary analyses (2019) (0)
- SELECTIVE INTERNAL RADIOTHERAPY (SIRT) IN METASTATIC COLORECTAL CANCER PATIENTS WITH LIVER METASTASES: PRELIMINARY PRIMARY CARE RESOURCE USE AND UTILITY RESULTS FROM THE FOXFIRE RANDOMISED CONTROLLED TRIAL (2017) (0)
- Magnetic resonance Imaging (MRI), liquid biopsies, and patient derived organoids (PDOs) as biomarkers of response to regorafenib (REG) in treatment-refractory metastatic colorectal cancer (mCRC) patients (pts). (2017) (0)
- bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases (2015) (0)
- Treatment Response Assessment Maps (TRAMs), a new tool for CNS lymphoma (2022) (0)
- RCHOPB: Feasibility study of RCHOP plus bevacizumab (B) in patients (pts) with diffuse large B-cell lymphoma (DLBCL). (2010) (0)
- The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab. (2012) (0)
- Gemcitabine (GEM), cisplatin (P) and methylprednisolone: A salvage regimen in relapsed Hodgkin's disease and non-Hodgkin's lymphoma (2004) (0)
- for identifying the (2016) (0)
- HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (2013) (0)
- Early interval and serial positron emission tomography‐computed tomography (PET‐CT) after an indeterminate response defined by a PET scored 4 on the Deauville scale in lymphoma (2020) (0)
- P-138 A comparison of the transcriptomic profiles of matched tissue from primary colorectal cancer and corresponding secondary lung metastases (2020) (0)
- ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C) (2023) (0)
- Genomic and Transcriptom ic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer (0)
- 447P The prognostic factors in early stage BRAF mutant colorectal cancer: Experience from a large volume UK tertiary centre (2021) (0)
- Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study (2018) (0)
- P PROGNOSIS IMPACT OF POSTOPERATIVE RADIATION IN PATIENTS WITH RADICAL ESOPHAGECTOMY AND PATHOLOGIC LYMPH NODES POSITIVE ESOPHAGEAL CANCER (2012) (0)
- The impact of treatment intent on overall survival after radiofrequency ablation of colorectal cancer liver metastases: The Royal Marsden Hospital experience. (2014) (0)
- CCR Drug Updates Ramucirumab : Successfully Targeting Angiogenesis in Gastric Cancer (2014) (0)
- Mutational processes impact the evolution of anti-EGFR antibody resistance in colorectal cancer (2020) (0)
- 580PQUALITY OF LIFE AND BOWEL FUNCTION IN LOCALLY ADVANCED RECTAL CANCER PATIENTS TREATED WITH AN INTENSIFIED NEOADJUVANT REGIMEN IN THE EXPERT-C TRIAL. (2014) (0)
- P1187: END OF TREATMENT 18F FDG-PET/CT RESPONSE IS PROGNOSTIC FOR OVERALL AND PROGRESSION-FREE SURVIVAL IN PERIPHERAL T-CELL LYMPHOMA: RESULTS OF THE UK NCRI PHASE 2 RANDOMISED CHEMO-T TRIAL PET/CT SUBSTUDY (2022) (0)
- Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty (2021) (0)
- Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer (2022) (0)
- [18F]Fluoromethylcholine PET/CT for CNS lymphoma assessment: a new tool (2021) (0)
- A prospective patient (pt) survey on clinical trials. (2015) (0)
- Abstract 69: Identification of new therapeutic targets and molecular predictors of response in oesophageal cancer (2016) (0)
- Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study (2022) (0)
- P-0235CARDIAC TOXICITY OF RALTITREXED IN HIGH-RISK PATIENTS – RESULTS OF A PATIENT AUDIT (2013) (0)
- Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial (2020) (0)
- FCγRIIa and FCγRIIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial. (2014) (0)
- Successful Long-Term Outcomes in Patients with Lymphoma Achieving Only Partial Response on [18f]FDG-PET Prior to Allogeneic Transplant (2014) (0)
- Analyses of PD-L1 and In fl ammatory Gene Expression Association with Ef fi cacy of Nivolumab (cid:1) Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer (2021) (0)
- SO-9 Pathological primary tumour and lymph node regression following neoadjuvant chemotherapy in resectable oesophagogastric cancer: Pooled analysis of 1619 patients from two randomised trials (2022) (0)
- Iconographies supplémentaires de l'article : FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis (2016) (0)
- Treatment of Gastroesophageal Junction Carcinoma (2017) (0)
- Rituximab, gemcitabine, cisplatin, and methylprednisolone (R-GEM-P) in treatment of relapsed diffuse large B-cell lymphoma (DLBCL). (2013) (0)
- PD-2 EMERGE: A multi-centre, non-randomised, single-arm phase II study investigating domatinostat plus avelumab in patients with previously treated advanced mismatch repair-proficient oesophagogastric and colorectal adenocarcinoma (2022) (0)
- 2343 Quality of life (QoL) as a prognostic factor for survival in previously treated advanced gastric or gastroesophageal junction (GEJ) cancer: Analysis of pooled data from two phase 3 studies (REGARD and RAINBOW) (2015) (0)
- Latest Research in Carcinoma of the Gastroesophageal Junction (2017) (0)
- Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study (2016) (0)
- The potential added value of F-18 fluoroethylcholine PET-CT(FCH) in assessment of viable disease in treated primary cerebral lymphoma (PCL) (2014) (0)
- Relationship Between Baseline Rectal Tumor Length and Magnetic Resonance Tumor Regression Grade Response to Chemoradiotherapy: A Subanalysis of the TRIGGER Feasibility Study (2022) (0)
- Aflibercept + FOLFIRI (AF) Versus. Placebo + FOLFIRI (PF) in Metastatic Colorectal Cancer (mCRC): Mean Overall Survival (OS) in a “Better Responders” Patient Population of the Velour Trial (2013) (0)
- The use of first, second and beyond line chemotherapy for metastatic pancreatic ductal adenocarcinoma at the Royal Marsden Hospital. (2019) (0)
- Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience (2018) (0)
- CN45 The Gastrointestinal and Lymphoma Unit Advanced Nurse Practitioner role in clinical research at The Royal Marsden Hospital (2022) (0)
- Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy. (2022) (0)
- 641P The influence of body composition on the systemic exposure of paclitaxel in esophageal cancer patients (2017) (0)
- 1704P Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH trial) (2021) (0)
- A feasibility study to evaluate the potential role of dynamic F-18 fluoroethyl choline PET-CT (FCH PET) in differentiating tumoral/radiation necrosis from viable brain tumor, compared to combined MRI/DWI. Does time activity curve (TAC) pattern analysis add value? (2013) (0)
- Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE. (2020) (0)
- Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): Safety and biomarker data from the ICONIC trial safety run-in (2019) (0)
- Heterogeneity of MYC amplification in oesophagogastric (OG) carcinoma: Results from a prospective screening study. (2017) (0)
- Comparative effectiveness of nivolumab (NIVO) relative to standard of care (SOC) for advanced/metastatic (adv/met) gastric or gastroesophageal junction cancer (GC/GEJC): A simulated treatment comparison (STC). (2019) (0)
- Abstracts reprinted from Journal of Clinical Oncology (2007) (0)
- P-309PROSPECT-R: A PROSPECTive translational study investigating molecular predictors of resistance and response to Regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (CRC) (2015) (0)
- Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer (2022) (0)
- Extranodal risk sites for CNS lymphoma: Review, good practice guide and the new SIHMIR paradigm shift (2022) (0)
- Epidemiology and etiology of gastric cancer (2011) (0)
- Study Ataxia Telangiectasia Mutated Protein Loss and Bene fi t From Oxaliplatin-based Chemotherapy in Colorectal Cancer (0)
- Identification of a nanostring signature that differentiates early pancreatic cancers according to stromal composition and predicts clinical outcome. (2019) (0)
- Comparison of the genetic profiles of primary colorectal cancers and their subsequent pulmonary metastases: Implications for targeted treatment. (2016) (0)
- Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty (2020) (0)
- 651PFACTORS ASSOCIATED WITH SECOND LINE PACLITAXEL EFFICACY IN NON-ASIAN PATIENTS (PTS) WITH ADVANCED OESOPHAGOGASTRIC (OG) CANCER. (2014) (0)
- Evolving Tissue and Circulating Biomarkers as Prognostic and Predictive Tools in Colorectal Cancer (2018) (0)
- Association of disease measurability, quality of life (QoL) and tumor status in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer (2016) (0)
- TOPIC HIGHLIGHT (2009) (0)
- Real-world outcomes of first-line U.S. patients with unresectable advanced or metastatic gastroesophageal adenocarcinoma by primary tumor location. (2020) (0)
- COMPARISON OF OUTCOMES BETWEEN PATIENTS WITH MYC REARRANGED DLBCL AND DOUBLE/ TRIPLE HIT HIGH‐GRADE B CELL LYMPHOMA: A PAN‐LONDON RETROSPECTIVE REVIEW (2019) (0)
- LEGEND: A randomised phase II study comparing lenalidomide plus rituximab, gemcitabine, and methylprednisolone (R-GEM-L) to rituximab, gemcitabine, methylprednisolone, and cisplatin (R-GEM-P) in second-line treatment of diffuse large B-cell lymphoma (DLBCL). (2014) (0)
- Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of response to DNA damage (2019) (0)
- The Value of Follow-up Following Complete Remission with Frontline Chemotherapy for DLBCL (2020) (0)
- Reporting of subgroup analyses (SGA) in phase III randomized trials in gastrointestinal (GI) cancer. (2013) (0)
- P-0175 Current Treatment Patterns in 1st (1L) and 2nd Line (2L) Treatment for Metastatic Colorectal Cancer (MCRC) in Western Europe (2012) (0)
- A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result. (2016) (0)
- Impact of mismatch repair (MMR) testing on colorectal cancer (CRC) oncology clinical practice. (2012) (0)
- Metastatic colorectal cancer (mCRC) patient derived organoids (PDOs) as a preclinical tool to understand mechanisms of resistance to anti-angiogenic drugs (2017) (0)
- Insulin-Like Growth Factor Receptor Inhibitors: Categorical Lack of Efficacy or Lack of Personalised Medicine? (2012) (0)
- Colorectal cancer trial endpoints: time for dynamic thinking? (2016) (0)
- A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications. (2023) (0)
- Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment (2021) (0)
- Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum (2015) (0)
- 453P Routine DPYD mutation testing for patients receiving fluoropyrimidines for gastrointestinal (GI) cancers: Real world experience in a tertiary UK oncology centre (2021) (0)
- A multicenter randomized phase II study of UFT/leucovorin and radiotherapy (RT) with or without cetuximab following induction gemcitabine plus capecitabine (GEM-CAP) in locally advanced pancreatic cancer (LAPC). (2010) (0)
- iSCORE: Immunotherapy sequencing in colon and rectal cancer (2019) (0)
- Formulating a surveillance strategy following surgery for oesophagogastric cancer. (2015) (0)
- MicroRNAs (miRs) as biomarkers of resistance to trastuzumab in HER2-positive oesophago-gastric cancer: Sub-study within the Planning Treatment for Oesophago-Gastric Cancer—A Randomised Maintenance Therapy Trial (PLATFORM). (2023) (0)
- A Phase II Study of Combined Cetuximab, Irinotecan, Oxaliplatin and Uft (ESCOUT) in Patients with Advanced Colorectal Cancer (ACRC) Incorporating Analysis of Circulating Tumour Cells (CTCS) (2012) (0)
- FOrMAT: Feasibility of a molecular characterization approach to treatment of patients (pts) with advanced gastrointestinal (GI) tumors (2015) (0)
- Comparison of Outcomes Between Patients with MYC Rearranged DLBCL and Double/Triple Hit High-Grade B-Cell Lymphoma: A Pan-London Retrospective Review (2019) (0)
- Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): EQ-5D, EORTC QLQ-C30 and LMC21 results from the FOXFIRE study (2017) (0)
- Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital (2022) (0)
- Is there still a place for radiotherapy in gastric cancer? (2023) (0)
- SOlar: A translational phase II study of single-agent olaparib in the treatment of advanced esophagogastric cancer. (2020) (0)
- Cancer of the Oesophagus (2007) (0)
- SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy (2022) (0)
- Longitudinal quality of life (QoL) and quality adjusted survival (QAS) in a randomised controlled trial (RCT) comparing bolus (24 weeks) vs. protracted venous infusion (PVI 12 weeks) 5-FU as adjuvant chemotherapy for colorectal cancer (CRC) (2004) (0)
- A global phase II trial-in-progress with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer. (2020) (0)
- Optimising diagnostic biopsies for molecular analysis in oesophagogastric cancer (2018) (0)
- Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases (2012) (0)
- 23OClonal diversity of MYC amplification evaluated by FISH and digital droplet polymerase chain reaction (ddPCR) in oesophagogastric (OG) cancer (2017) (0)
- MESH: Phase II trial of methotrexate as a synthetic lethal therapy for metastatic MSH2-deficient colorectal and other tumors. (2010) (0)
- Exclusion of patients with prior cancers from clinical trials: Is this justified? (2014) (0)
- KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer (2018) (0)
- Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma? (2021) (0)
- Evaluation of the role of MRI in staging rectal cancer within the multidisciplinary team setting. (2004) (0)
- Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer (2022) (0)
- Prognostic value of pretreatment 18F-FDG-PET/CT in colorectal liver metastasis (2010) (0)
- Prognostication in esophagogastric adenocarcinoma (OGA): Factors influencing overall survival (OS) in REAL3. (2014) (0)
- Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience (2015) (0)
- Residual Disease on FDG-PET and Multiple Lines of Prior Therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem Cell Transplantation for Lymphoma (2014) (0)
- 116PClinical and pre-clinical biomarkers of Regorafenib (REG) efficacy in metastatic colorectal cancer (mCRC) in a phase II trial (2017) (0)
- Trends in resected oesophageal and gastric adenocarcinoma (OGA) outcomes: Royal Marsden (RM) experience 2001-2010. (2015) (0)
- Fifteen-year experience of all patients (pts) with small bowel adenocarcinoma (SBA), treated in a specialized gastrointestinal (GI) oncology unit: Royal Marsden (RM) experience. (2014) (0)
- 87P Infliximab use in patients with checkpoint inhibitor toxicities: A tertiary centre experience (2022) (0)
- PGI15 - HEALTHCARE RESOURCE UTILIZATION (HCRU) IN METASTATIC OR UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER PATIENTS RECEIVING SECOND-LINE TREATMENT (2018) (0)
- 343 Epidermal growth factor receptor (EGFR) therapies in colorectal carcinoma — the European data (2003) (0)
- Ultra-sensitive mutation detection and genome-wide DNA copy 11 number reconstruction by error corrected circulating tumor DNA 12 sequencing 13 14 (2018) (0)
- Is front-line checkpoint blockade ATTRACTIVE in advanced gastric cancer? (2019) (0)
- A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI (2014) (0)
- P-079Impact of disease biology and stage on outcomes for oesophageal and gastric adenocarcinoma (OGA) treated with neoadjuvant chemotherapy (2015) (0)
- 189PFCγRIIa and FCγRIIIa single nucleotide polymorphisms (SNPs) and cetuximab benefit in the EXCITE trial (2017) (0)
- Toxicity and efficacy of salvage paclitaxel chemotherapy in Royal Marsden (RM) oesophagogastric adenocarcinoma (OGA) patients (pts). (2015) (0)
- The overexpression of EGFR and upregulation of the phosphatidylinositol 3-kinase Treatment Advance Relevant Study Results Early Gastric Cancer Advanced Gastric Cancer Early Esophageal Squamous Cell Cancer Advanced Hepatocellular Carcinoma Advanced Biliary Tract Cancer Examples of Major Advances in t (2011) (0)
- 597PReal world use of palliative systemic therapy (tx) in patients (pts) with metastatic early onset colorectal cancer (mEOCRC) within a UK specialist cancer centre (2017) (0)
- Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ian Chau?
Ian Chau is affiliated with the following schools:
